Your browser is no longer supported. Please, upgrade your browser.
Settings
AFIB Acutus Medical, Inc. daily Stock Chart
AFIB [NASD]
Acutus Medical, Inc.
Index- P/E- EPS (ttm)-4.08 Insider Own2.30% Shs Outstand28.43M Perf Week-10.54%
Market Cap712.17M Forward P/E- EPS next Y-2.67 Insider Trans0.00% Shs Float27.20M Perf Month-17.11%
Income-100.40M PEG- EPS next Q-0.99 Inst Own53.30% Short Float3.11% Perf Quarter-
Sales3.60M P/S197.83 EPS this Y-102.60% Inst Trans- Short Ratio2.89 Perf Half Y-
Book/sh- P/B- EPS next Y51.50% ROA- Target Price36.75 Perf Year-
Cash/sh1.76 P/C14.27 EPS next 5Y- ROE- 52W Range24.00 - 38.99 Perf YTD-5.47%
Dividend- P/FCF- EPS past 5Y- ROI42.60% 52W High-35.75% Beta-
Dividend %- Quick Ratio2.10 Sales past 5Y- Gross Margin- 52W Low4.37% ATR1.56
Employees224 Current Ratio2.60 Sales Q/Q54.50% Oper. Margin- RSI (14)36.38 Volatility4.69% 5.24%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.89 Prev Close25.25
ShortableYes LT Debt/Eq- EarningsSep 17 AMC Payout- Avg Volume291.90K Price25.05
Recom1.60 SMA20-10.82% SMA50-15.80% SMA200-15.38% Volume260,584 Change-0.79%
Aug-31-20Initiated William Blair Outperform
Aug-31-20Initiated JP Morgan Overweight $39
Aug-31-20Initiated Canaccord Genuity Hold $30
Aug-31-20Initiated BTIG Research Buy $40
Aug-31-20Initiated BofA Securities Buy $38
Sep-17-20 04:01PM  
04:01PM  
02:30PM  
Sep-08-20 08:30AM  
Sep-03-20 04:01PM  
Aug-20-20 04:58PM  
Aug-10-20 04:41PM  
Aug-05-20 08:30PM  
Acutus Medical, Inc., an arrhythmia management company, designs, manufactures, and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. It offers AcQMap console and workstation, an advanced imaging, navigation, and mapping system for physicians to map, treat, re-map, and adjust additional therapy as needed; and Patient Electrode Kit that is required in every procedure to provide cardiac signals, catheter localization, and AcQMap system grounding. The company also provides diagnostic and monitoring devices, such as AcQMap 3D Imaging and Mapping Catheter that is used for mapping during the electrophysiology procedures; conventional diagnostic catheters, including multi-polar, steerable, and loop catheters that are used during the mapping and ablation procedures; and reprocessed diagnostic catheters, such as diagnostic, multipole, fixed, steerable, and advanced mapping and imaging catheters. In addition, the company provides access devices, which include AcQRef Introducer that provides stable electrical reference and vascular access; AcQGuide MAX Steerable Introducer, which provides a stable platform for catheter passage and precision placement; and Transseptal Access Products. Further, it offers therapeutic devices, such as AcQBlate FORCE Ablation Catheters, AlCath Ablation Catheters, MedFact Robotic Navigation Enabled Ablation Catheters, Qubic Force, Qubic RF Generator and Pulse Stimulator, and Qiona Pump. The company also provides various software mapping modes comprises single position, supermap, contact mapping, and stereotaxis integration. Acutus Medical, Inc. was founded in 2011 and is based in Carlsbad, California.
ANNX Annexon, Inc. daily Stock Chart
ANNX [NASD]
Annexon, Inc.
Index- P/E- EPS (ttm)-0.24 Insider Own- Shs Outstand36.69M Perf Week-8.92%
Market Cap962.38M Forward P/E- EPS next Y-1.65 Insider Trans- Shs Float22.69M Perf Month18.26%
Income-44.80M PEG- EPS next Q-0.35 Inst Own32.30% Short Float5.25% Perf Quarter-
Sales- P/S- EPS this Y-107.10% Inst Trans- Short Ratio3.97 Perf Half Y-
Book/sh- P/B- EPS next Y17.10% ROA-64.30% Target Price33.00 Perf Year-
Cash/sh3.40 P/C7.71 EPS next 5Y38.60% ROE42.40% 52W Range15.33 - 31.84 Perf YTD47.69%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-17.62% Beta-
Dividend %- Quick Ratio9.90 Sales past 5Y- Gross Margin- 52W Low71.10% ATR2.37
Employees30 Current Ratio9.90 Sales Q/Q- Oper. Margin- RSI (14)47.12 Volatility8.93% 9.94%
OptionableNo Debt/Eq- EPS Q/Q-29.40% Profit Margin- Rel Volume0.21 Prev Close27.71
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume300.03K Price26.23
Recom1.70 SMA20-4.53% SMA501.72% SMA2006.72% Volume64,844 Change-5.34%
Aug-18-20Initiated JP Morgan Overweight $33
Aug-18-20Initiated Cowen Outperform
Aug-18-20Initiated BofA Securities Buy $33
Sep-08-20 04:01PM  
Jul-30-20 08:00AM  
Jul-28-20 04:05PM  
Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune and neurodegenerative diseases. It focuses on the treatment of body, brain, and eye disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, which has completed Phase 1b clinical trials to treat patients with guillain- barre syndrome; and ANX007, which has completed Phase 1b clinical trials to treat patients with glaucoma. The company's candidates also comprise ANX005 that has completed preclinical trials to treat patients with warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis; ANX007, which has completed preclinical trials for the treatment of geographic atrophy; and ANX009 that has completed preclinical trials for the treatment of systemic autoimmune diseases. The company was founded in 2011 and is headquartered in South San Francisco, California.
NKTX Nkarta, Inc. daily Stock Chart
NKTX [NASD]
Nkarta, Inc.
Index- P/E- EPS (ttm)- Insider Own9.70% Shs Outstand31.83M Perf Week-7.93%
Market Cap872.46M Forward P/E- EPS next Y-1.89 Insider Trans336.48% Shs Float27.81M Perf Month-19.67%
Income- PEG- EPS next Q-0.38 Inst Own68.00% Short Float5.74% Perf Quarter-9.69%
Sales0.00M P/S- EPS this Y- Inst Trans- Short Ratio8.00 Perf Half Y-
Book/sh- P/B- EPS next Y90.80% ROA- Target Price43.33 Perf Year-
Cash/sh0.68 P/C40.39 EPS next 5Y- ROE- 52W Range22.46 - 58.69 Perf YTD-42.78%
Dividend- P/FCF- EPS past 5Y- ROI90.60% 52W High-53.30% Beta-
Dividend %- Quick Ratio0.40 Sales past 5Y- Gross Margin- 52W Low22.04% ATR3.26
Employees70 Current Ratio0.40 Sales Q/Q- Oper. Margin- RSI (14)42.35 Volatility13.85% 10.46%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume2.42 Prev Close29.12
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume199.75K Price27.41
Recom1.70 SMA20-11.96% SMA50-6.68% SMA200-8.02% Volume471,430 Change-5.87%
Aug-04-20Initiated Stifel Buy $41
Aug-04-20Initiated Mizuho Buy $34
Aug-04-20Initiated Evercore ISI Outperform $55
Aug-04-20Initiated Cowen Outperform
Oct-12-20 11:03AM  
Oct-05-20 04:02PM  
Sep-29-20 08:02AM  
Sep-08-20 04:02PM  
Aug-20-20 04:02PM  
Jul-31-20 04:42PM  
Jul-14-20 04:39PM  
04:15PM  
Jul-10-20 11:30AM  
08:09AM  
12:44AM  
Nkarta, Inc., a biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its co-lead product candidates are NKX101, a pre-clinical product that enhances the power of innate NK biology to detect and kill cancerous cells; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company was founded in 2015 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flynn James EPossible Member of 10% GroupJul 14Buy18.001,000,00018,000,0001,209,936Jul 14 11:39 AM
Florence Anthony A. Jr.10% OwnerJul 14Buy18.00666,66611,999,9882,902,115Jul 16 05:00 PM
BASKETT FOREST10% OwnerJul 14Buy18.00666,66611,999,9882,902,115Jul 16 05:00 PM
MAKOWER JOSHUA10% OwnerJul 14Buy18.00666,66611,999,9882,902,115Jul 16 05:00 PM
Makhzoumi Mohamad10% OwnerJul 14Buy18.00666,66611,999,9882,902,115Jul 16 05:00 PM
Sonsini Peter W.10% OwnerJul 14Buy18.00666,66611,999,9882,902,115Jul 16 05:00 PM
SANDELL SCOTT D10% OwnerJul 14Buy18.00666,66611,999,9882,902,115Jul 16 05:00 PM
New Enterprise Associates 15, 10% OwnerJul 14Buy18.00666,66611,999,9882,902,115Jul 16 05:00 PM
Novo Holdings A/S10% OwnerJul 14Buy18.00555,5559,999,9902,793,865Jul 16 04:41 PM
RA CAPITAL MANAGEMENT, L.P.10% OwnerJul 14Buy18.003,333,33359,999,9945,605,129Jul 16 04:30 PM
GLAXOSMITHKLINE PLCDirectorJul 14Buy18.00833,33314,999,9943,150,732Jul 16 08:13 PM
GBIO Generation Bio Co. daily Stock Chart
GBIO [NASD]
Generation Bio Co.
Index- P/E- EPS (ttm)-1.26 Insider Own14.70% Shs Outstand45.03M Perf Week-11.08%
Market Cap1.04B Forward P/E- EPS next Y-2.23 Insider Trans0.00% Shs Float39.39M Perf Month-21.31%
Income-67.60M PEG- EPS next Q-0.45 Inst Own89.40% Short Float3.61% Perf Quarter8.22%
Sales- P/S- EPS this Y-71.30% Inst Trans1.04% Short Ratio9.37 Perf Half Y-
Book/sh6.75 P/B3.32 EPS next Y23.10% ROA- Target Price32.67 Perf Year-
Cash/sh6.48 P/C3.45 EPS next 5Y- ROE- 52W Range17.00 - 32.18 Perf YTD-9.36%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-30.45% Beta-
Dividend %- Quick Ratio26.50 Sales past 5Y- Gross Margin- 52W Low31.65% ATR2.37
Employees85 Current Ratio26.50 Sales Q/Q- Oper. Margin- RSI (14)33.23 Volatility10.31% 8.68%
OptionableNo Debt/Eq0.00 EPS Q/Q-61.20% Profit Margin- Rel Volume0.44 Prev Close22.27
ShortableYes LT Debt/Eq0.00 EarningsAug 11 BMO Payout- Avg Volume151.82K Price22.38
Recom1.50 SMA20-19.83% SMA50-17.11% SMA200-7.48% Volume66,250 Change0.49%
Jul-07-20Initiated Wedbush Outperform $31
Jul-07-20Initiated JP Morgan Overweight $28
Jul-07-20Initiated Jefferies Buy $38
Jul-07-20Initiated Cowen Outperform
Oct-05-20 06:30AM  
Sep-24-20 06:30AM  
Sep-14-20 10:59AM  
Aug-11-20 06:30AM  
Aug-05-20 06:30AM  
Jul-22-20 07:00AM  
Jun-16-20 04:02PM  
Jun-12-20 12:31PM  
06:24AM  
Jun-11-20 09:52PM  
Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of eight programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was founded in 2016 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Angelino Mark D.Chief Operating OfficerAug 14Option Exercise0.6062,56037,536345,637Aug 18 04:07 PM
RVMD Revolution Medicines, Inc. daily Stock Chart
RVMD [NASD]
Revolution Medicines, Inc.
Index- P/E- EPS (ttm)-21.25 Insider Own0.40% Shs Outstand58.75M Perf Week-11.70%
Market Cap2.50B Forward P/E- EPS next Y-1.67 Insider Trans-65.71% Shs Float43.70M Perf Month16.01%
Income- PEG- EPS next Q-0.39 Inst Own71.80% Short Float7.70% Perf Quarter48.27%
Sales46.17M P/S54.09 EPS this Y-13.70% Inst Trans0.07% Short Ratio7.91 Perf Half Y38.67%
Book/sh6.14 P/B6.28 EPS next Y7.70% ROA- Target Price42.25 Perf Year-
Cash/sh5.02 P/C7.67 EPS next 5Y- ROE- 52W Range17.34 - 47.14 Perf YTD33.39%
Dividend- P/FCF- EPS past 5Y- ROI32.60% 52W High-18.22% Beta-
Dividend %- Quick Ratio7.80 Sales past 5Y- Gross Margin- 52W Low122.25% ATR2.47
Employees106 Current Ratio7.80 Sales Q/Q-24.20% Oper. Margin- RSI (14)52.09 Volatility7.62% 6.31%
OptionableNo Debt/Eq0.00 EPS Q/Q-113.40% Profit Margin- Rel Volume1.16 Prev Close42.70
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume425.58K Price38.55
Recom1.80 SMA20-0.57% SMA5019.25% SMA20027.92% Volume489,466 Change-9.72%
May-21-20Initiated H.C. Wainwright Buy $55
Mar-09-20Initiated JP Morgan Neutral $32
Mar-09-20Initiated Guggenheim Buy $50
Mar-09-20Initiated Cowen Outperform
Oct-12-20 07:30AM  
Sep-22-20 08:52AM  
Sep-18-20 04:16PM  
Sep-16-20 09:00AM  
Sep-09-20 07:30AM  
Sep-08-20 07:30AM  
Aug-28-20 11:12AM  
Aug-10-20 07:30AM  
Jul-13-20 04:01PM  
08:53AM  
Jul-06-20 04:01PM  
Jun-30-20 04:05PM  
Jun-22-20 04:01PM  
07:30AM  
Jun-18-20 07:30AM  
Jun-09-20 07:30AM  
May-22-20 10:29PM  
May-19-20 07:30AM  
May-14-20 04:05PM  
Apr-29-20 08:05AM  
Mar-18-20 07:30AM  
Mar-09-20 07:30AM  
Feb-18-20 04:01PM  
Feb-14-20 01:24PM  
Feb-13-20 11:20AM  
Feb-12-20 07:56PM  
07:39PM  
Feb-11-20 07:12AM  
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit targets primarily within the RAS and mTOR signaling pathways. The company's principal product candidate is RMC-4630, an inhibitor of SHP2, which is in Phase 1b/2 study for the treatment of RAS-dependent tumors. Its products in preclinical stage include mutant RAS proteins; SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a mTORC1 inhibitor. Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors. The company was founded in 2014 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ANDERSON ELIZABETH MDirectorOct 15Sale45.004,780215,10026,990Oct 15 07:15 PM
Anders JackSee RemarksOct 13Option Exercise2.6810,00026,80010,000Oct 15 07:14 PM
ANDERSON ELIZABETH MDirectorOct 13Sale45.002209,90031,770Oct 15 07:15 PM
Anders JackSee RemarksOct 13Sale44.0010,000440,0000Oct 15 07:14 PM
Anders JackSee RemarksOct 06Option Exercise2.6810,00026,80010,000Oct 08 05:07 PM
Miller Vincent A.DirectorOct 06Sale39.006,250243,75020,133Oct 08 05:07 PM
ANDERSON ELIZABETH MDirectorOct 06Sale40.005,000200,00031,990Oct 08 05:06 PM
Anders JackSee RemarksOct 06Sale40.0010,000400,0000Oct 08 05:07 PM
Weber BarbaraDirectorOct 05Option Exercise1.127,1968,0609,004Oct 05 08:17 PM
Weber BarbaraDirectorOct 05Sale36.177,196260,3131,808Oct 05 08:17 PM
Weber BarbaraDirectorOct 02Option Exercise1.128049002,612Oct 05 08:17 PM
Horn Margaret ASee RemarksOct 02Sale35.4012,495442,32153,302Oct 02 07:01 PM
Weber BarbaraDirectorOct 02Sale36.0280428,9601,808Oct 05 08:17 PM
Weber BarbaraDirectorOct 01Option Exercise1.122,0002,2403,808Oct 05 08:17 PM
Weber BarbaraDirectorOct 01Sale34.762,00069,5211,808Oct 05 08:17 PM
Horn Margaret ASee RemarksOct 01Sale35.0157,5052,013,17065,797Oct 02 07:01 PM
Kelsey Stephen MichaelSee RemarksSep 30Option Exercise4.7317,24881,583253,577Sep 30 08:31 PM
GOLDSMITH MARK ASee RemarksSep 30Option Exercise4.7342,578201,28642,578Sep 30 08:32 PM
GOLDSMITH MARK ASee RemarksSep 30Sale34.121,31244,76271,879Sep 30 08:32 PM
GOLDSMITH MARK ASee RemarksSep 30Sale34.4042,5781,464,8540Sep 30 08:32 PM
Kelsey Stephen MichaelSee RemarksSep 30Sale34.3317,248592,060236,329Sep 30 08:31 PM
Kelsey Stephen MichaelSee RemarksSep 29Option Exercise4.7313,26862,758249,597Sep 30 08:31 PM
GOLDSMITH MARK ASee RemarksSep 29Option Exercise4.5130,523137,68830,523Sep 30 08:32 PM
GOLDSMITH MARK ASee RemarksSep 29Sale34.0821,088718,65273,191Sep 30 08:32 PM
GOLDSMITH MARK ASee RemarksSep 29Sale34.1430,5231,041,9180Sep 30 08:32 PM
Kelsey Stephen MichaelSee RemarksSep 29Sale34.1413,268452,914236,329Sep 30 08:31 PM
Miller Vincent A.DirectorSep 29Sale34.0745015,33226,383Sep 30 08:33 PM
Kelsey Stephen MichaelSee RemarksSep 28Option Exercise4.739,38444,386245,713Sep 30 08:31 PM
GOLDSMITH MARK ASee RemarksSep 28Option Exercise4.0910,13241,44010,132Sep 30 08:32 PM
Miller Vincent A.DirectorSep 28Sale34.115,300180,77226,833Sep 30 08:33 PM
Kelsey Stephen MichaelSee RemarksSep 28Sale34.089,384319,831236,329Sep 30 08:31 PM
GOLDSMITH MARK ASee RemarksSep 28Sale34.087,500255,60594,279Sep 30 08:32 PM
GOLDSMITH MARK ASee RemarksSep 28Sale34.1110,132345,5670Sep 30 08:32 PM
Kelsey Stephen MichaelSee RemarksSep 23Option Exercise4.73100473236,429Sep 23 08:35 PM
GOLDSMITH MARK ASee RemarksSep 23Option Exercise4.09100409100Sep 23 08:36 PM
Miller Vincent A.DirectorSep 23Sale34.0250017,01032,133Sep 25 04:29 PM
GOLDSMITH MARK ASee RemarksSep 23Sale34.021003,402101,779Sep 23 08:36 PM
GOLDSMITH MARK ASee RemarksSep 23Sale34.011003,4010Sep 23 08:36 PM
Kelsey Stephen MichaelSee RemarksSep 23Sale34.021003,402236,329Sep 23 08:35 PM
GOLDSMITH MARK ASee RemarksSep 22Option Exercise4.0910,09741,29710,097Sep 23 08:36 PM
Kelsey Stephen MichaelSee RemarksSep 22Sale33.00983,234236,329Sep 23 08:35 PM
GOLDSMITH MARK ASee RemarksSep 22Sale33.0054117,853101,879Sep 23 08:36 PM
GOLDSMITH MARK ASee RemarksSep 22Sale33.1510,097334,7130Sep 23 08:36 PM
GOLDSMITH MARK ASee RemarksSep 21Option Exercise4.0929,903122,30329,903Sep 23 08:36 PM
Kelsey Stephen MichaelSee RemarksSep 21Sale33.0014,902491,805236,427Sep 23 08:35 PM
GOLDSMITH MARK ASee RemarksSep 21Sale33.0011,459378,173102,420Sep 23 08:36 PM
GOLDSMITH MARK ASee RemarksSep 21Sale33.0029,903986,8500Sep 23 08:36 PM
GOLDSMITH MARK ASee RemarksSep 18Option Exercise3.577,34226,2097,342Sep 18 08:01 PM
GOLDSMITH MARK ASee RemarksSep 18Sale31.0571222,106113,879Sep 18 08:01 PM
GOLDSMITH MARK ASee RemarksSep 18Sale31.677,342232,5210Sep 18 08:01 PM
Kelsey Stephen MichaelSee RemarksSep 18Sale31.0363719,767251,329Sep 18 08:00 PM
GOLDSMITH MARK ASee RemarksSep 17Option Exercise1.1227,36330,64727,363Sep 18 08:01 PM
GOLDSMITH MARK ASee RemarksSep 17Sale31.0311,288350,311114,591Sep 18 08:01 PM
GOLDSMITH MARK ASee RemarksSep 17Sale30.8227,363843,2210Sep 18 08:01 PM
Kelsey Stephen MichaelSee RemarksSep 17Sale31.0311,363352,556251,966Sep 18 08:00 PM
GOLDSMITH MARK ASee RemarksSep 16Option Exercise1.128,8139,8718,813Sep 18 08:01 PM
GOLDSMITH MARK ASee RemarksSep 16Sale29.048,813255,9560Sep 18 08:01 PM
GOLDSMITH MARK ASee RemarksSep 10Option Exercise1.122,5442,8492,544Sep 11 06:35 PM
Kelsey Stephen MichaelSee RemarksSep 10Option Exercise4.731,0024,739265,871Sep 10 09:30 PM
Kelsey Stephen MichaelSee RemarksSep 10Sale29.062,54273,880263,329Sep 10 09:30 PM
GOLDSMITH MARK ASee RemarksSep 10Sale29.004,399127,571125,879Sep 11 06:35 PM
GOLDSMITH MARK ASee RemarksSep 10Sale29.072,54473,9480Sep 11 06:35 PM
GOLDSMITH MARK ASee RemarksSep 09Sale29.001002,900130,251Sep 11 06:35 PM
Kelsey Stephen MichaelSee RemarksSep 09Sale29.041002,904264,869Sep 10 09:30 PM
Kelsey Stephen MichaelSee RemarksSep 08Option Exercise4.736002,838266,369Sep 10 09:30 PM
GOLDSMITH MARK ASee RemarksSep 08Option Exercise1.129001,008900Sep 10 09:31 PM
GOLDSMITH MARK ASee RemarksSep 08Sale29.0590026,1450Sep 10 09:31 PM
Kelsey Stephen MichaelSee RemarksSep 08Sale29.061,40040,683264,969Sep 10 09:30 PM
GOLDSMITH MARK ASee RemarksSep 08Sale29.0590026,141130,351Sep 10 09:31 PM
Kelsey Stephen MichaelSee RemarksSep 03Option Exercise4.737003,311267,169Sep 03 07:55 PM
GOLDSMITH MARK ASee RemarksSep 03Option Exercise1.12500560500Sep 04 07:05 PM
GOLDSMITH MARK ASee RemarksSep 03Sale29.0770020,352131,251Sep 04 07:05 PM
GOLDSMITH MARK ASee RemarksSep 03Sale29.0750014,5330Sep 04 07:05 PM
Kelsey Stephen MichaelSee RemarksSep 03Sale29.071,40040,699265,769Sep 03 07:55 PM
Kelsey Stephen MichaelSee RemarksSep 02Option Exercise4.73100473267,295Sep 03 07:55 PM
GOLDSMITH MARK ASee RemarksSep 02Option Exercise1.121,1001,2321,100Sep 04 07:05 PM
GOLDSMITH MARK ASee RemarksSep 02Sale29.0280023,213131,951Sep 04 07:05 PM
GOLDSMITH MARK ASee RemarksSep 02Sale29.051,10031,9600Sep 04 07:05 PM
Kelsey Stephen MichaelSee RemarksSep 02Sale29.0282623,973266,469Sep 03 07:55 PM
Kelsey Stephen MichaelSee RemarksSep 01Option Exercise4.6810,00046,841277,195Sep 03 07:55 PM
Kelsey Stephen MichaelSee RemarksSep 01Sale27.6710,000276,722267,195Sep 03 07:55 PM
Kelsey Stephen MichaelSee RemarksAug 28Option Exercise4.09118483267,313Aug 31 07:08 PM
Kelsey Stephen MichaelSee RemarksAug 28Sale29.001183,422267,195Aug 31 07:08 PM
GOLDSMITH MARK ASee RemarksAug 27Option Exercise1.121,4381,6111,438Aug 31 07:09 PM
Kelsey Stephen MichaelSee RemarksAug 27Option Exercise4.098003,272268,809Aug 31 07:08 PM
GOLDSMITH MARK ASee RemarksAug 27Sale29.011,10131,939132,751Aug 31 07:09 PM
GOLDSMITH MARK ASee RemarksAug 27Sale29.011,43841,7130Aug 31 07:09 PM
Kelsey Stephen MichaelSee RemarksAug 27Sale29.011,61446,825267,195Aug 31 07:08 PM
Weber BarbaraDirectorAug 13Option Exercise1.123333732,141Aug 14 06:30 PM
Kelsey Stephen MichaelSee RemarksAug 13Option Exercise4.094,90020,041271,809Aug 14 06:31 PM
GOLDSMITH MARK ASee RemarksAug 13Option Exercise1.129,70010,8645,232Aug 14 06:32 PM
Kelsey Stephen MichaelSee RemarksAug 13Sale27.554,900134,995268,009Aug 14 06:31 PM
Weber BarbaraDirectorAug 13Sale28.003339,3241,808Aug 14 06:30 PM
GOLDSMITH MARK ASee RemarksAug 13Sale27.573,900107,522133,852Aug 14 06:32 PM
GOLDSMITH MARK ASee RemarksAug 13Sale27.929,700270,7860Aug 14 06:32 PM
GOLDSMITH MARK ASee RemarksAug 12Option Exercise1.1216,96719,00314,584Aug 14 06:32 PM
Weber BarbaraDirectorAug 12Option Exercise1.121,6671,8673,475Aug 14 06:30 PM
Kelsey Stephen MichaelSee RemarksAug 12Option Exercise4.0910,10041,309277,107Aug 14 06:31 PM
GOLDSMITH MARK ASee RemarksAug 12Sale25.916,100158,054137,752Aug 14 06:32 PM
GOLDSMITH MARK ASee RemarksAug 12Sale25.9216,967439,7600Aug 14 06:32 PM
SDGR Schrodinger, Inc. daily Stock Chart
SDGR [NASD]
Schrodinger, Inc.
Index- P/E- EPS (ttm)-0.69 Insider Own10.70% Shs Outstand63.30M Perf Week-1.29%
Market Cap3.65B Forward P/E- EPS next Y-0.20 Insider Trans-47.96% Shs Float23.77M Perf Month9.21%
Income-35.50M PEG- EPS next Q-0.07 Inst Own38.90% Short Float21.55% Perf Quarter-31.89%
Sales95.10M P/S38.39 EPS this Y13.60% Inst Trans-7.09% Short Ratio3.50 Perf Half Y23.21%
Book/sh4.68 P/B11.93 EPS next Y57.40% ROA-14.00% Target Price87.25 Perf Year-
Cash/sh4.34 P/C12.85 EPS next 5Y- ROE-34.50% 52W Range25.50 - 99.50 Perf YTD94.97%
Dividend- P/FCF- EPS past 5Y- ROI41.10% 52W High-43.88% Beta-
Dividend %- Quick Ratio7.10 Sales past 5Y- Gross Margin58.30% 52W Low118.98% ATR3.14
Employees392 Current Ratio7.10 Sales Q/Q21.60% Oper. Margin-50.50% RSI (14)49.75 Volatility4.38% 5.84%
OptionableYes Debt/Eq0.00 EPS Q/Q-550.20% Profit Margin-37.30% Rel Volume1.01 Prev Close55.67
ShortableYes LT Debt/Eq0.00 EarningsAug 10 BMO Payout- Avg Volume1.46M Price55.84
Recom2.20 SMA204.36% SMA50-3.35% SMA200-2.80% Volume1,472,808 Change0.31%
Oct-12-20Upgrade Jefferies Hold → Buy
Mar-02-20Initiated Morgan Stanley Equal-Weight $43
Mar-02-20Initiated Jefferies Hold $42
Mar-02-20Initiated BMO Capital Markets Outperform $65
Oct-08-20 01:20PM  
Sep-25-20 11:25AM  
Sep-21-20 09:19AM  
Sep-14-20 09:38AM  
Sep-08-20 07:00AM  
Aug-28-20 03:11PM  
Aug-17-20 04:30PM  
Aug-14-20 09:57AM  
Aug-13-20 12:07PM  
Aug-12-20 10:00PM  
Aug-10-20 04:08PM  
04:00PM  
06:00AM  
Aug-07-20 08:46AM  
Aug-06-20 02:47PM  
Aug-03-20 07:00AM  
Jul-28-20 07:00AM  
Jun-23-20 07:00AM  
07:00AM  
Jun-16-20 07:00AM  
May-28-20 04:00PM  
May-15-20 10:54AM  
May-13-20 07:00AM  
May-06-20 07:00AM  
May-04-20 07:00AM  
Mar-23-20 07:00AM  
Mar-02-20 07:00AM  
Feb-10-20 04:05PM  
Feb-05-20 08:45PM  
Schrodinger, Inc. provides computational platform to accelerate drug discovery and materials design for biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. The company operates through two segments, Software and Drug Discovery. It segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment develops a pipeline of preclinical and clinical drug discovery programs through its computational platform in collaboration with pharmaceutical companies. Schrodinger, Inc. has strategic collaborations with Twist Bioscience Corporation; and Thermo Fisher Scientific to extend the use of cryo-EM in connection with in silico compound screening to accelerate drug discovery. The company was founded in 1990 and is based in New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SHAW DAVID E10% OwnerOct 21Sale55.94155,7118,710,00212,876,334Oct 21 07:02 PM
SHAW DAVID E10% OwnerOct 20Sale56.34131,2967,396,98113,032,045Oct 21 07:02 PM
SHAW DAVID E10% OwnerOct 19Sale57.42187,44610,763,13813,163,341Oct 21 07:02 PM
SHAW DAVID E10% OwnerOct 15Sale55.79156,4668,729,62313,350,787Oct 15 06:43 PM
SHAW DAVID E10% OwnerOct 14Sale59.11304,14017,978,52413,507,253Oct 15 06:43 PM
SHAW DAVID E10% OwnerOct 13Sale59.32244,69814,515,03013,811,393Oct 15 06:43 PM
Lorton Kenneth PatrickSee RemarksOct 09Option Exercise3.076,68820,53247,325Oct 13 04:25 PM
SHAW DAVID E10% OwnerOct 09Sale55.99472,63426,462,70814,056,091Oct 09 07:01 PM
SHAW DAVID E10% OwnerOct 08Sale54.44231,09812,581,56714,528,725Oct 09 07:01 PM
SHAW DAVID E10% OwnerOct 07Sale53.86216,06111,637,6900Oct 09 07:01 PM
Lorton Kenneth PatrickSee RemarksOct 01Option Exercise4.345572,41740,637Oct 02 05:06 PM
SHAW DAVID E10% OwnerSep 30Sale48.41178,3668,635,23685,039Sep 30 08:51 PM
SHAW DAVID E10% OwnerSep 29Sale47.81155,0007,411,120263,405Sep 30 08:51 PM
SHAW DAVID E10% OwnerSep 28Sale48.38154,8407,491,517418,405Sep 30 08:51 PM
SHAW DAVID E10% OwnerSep 24Sale47.58150,0007,137,610573,245Sep 24 07:13 PM
SHAW DAVID E10% OwnerSep 23Sale50.54158,3888,004,856723,245Sep 24 07:13 PM
SHAW DAVID E10% OwnerSep 22Sale51.40145,5257,479,261881,633Sep 24 07:13 PM
SHAW DAVID E10% OwnerSep 17Sale51.67159,9238,263,9690Sep 17 08:10 PM
Farid RamySee RemarksSep 16Sale53.2220,0001,064,304184,432Sep 18 04:25 PM
SHAW DAVID E10% OwnerSep 16Sale53.23208,00111,071,98653,923Sep 17 08:10 PM
SHAW DAVID E10% OwnerSep 15Sale53.97205,96511,116,805261,924Sep 17 08:10 PM
Herman JennyVice President, ControllerAug 21Sale70.001,00070,0002,220Aug 25 04:09 PM
Lebowitz JoelSee RemarksAug 19Option Exercise4.34117,051508,001117,051Aug 21 04:28 PM
Lebowitz JoelSee RemarksAug 19Sale67.77117,0517,932,1890Aug 21 04:28 PM
Herman JennyVice President, ControllerAug 19Sale67.772,000135,5313,220Aug 21 04:24 PM
Akinsanya KarenSee RemarksAug 17Option Exercise2.923,3449,7643,344Aug 19 04:19 PM
Lorton Kenneth PatrickSee RemarksAug 17Option Exercise3.917,97031,19340,080Aug 19 04:18 PM
Friesner RichardDirectorAug 17Sale62.04500,00031,020,000605,450Aug 17 04:13 PM
Akinsanya KarenSee RemarksAug 17Sale68.043,344227,5200Aug 19 04:19 PM
BILL & MELINDA GATES FOUNDATIO10% OwnerAug 17Sale64.241,836,337117,966,2894,981,664Aug 18 07:09 PM
BILL & MELINDA GATES FOUNDATIO10% OwnerAug 14Sale70.40163,66311,522,4226,818,001Aug 18 07:09 PM
Farid RamySee RemarksAug 13Sale70.5950,0003,529,528204,432Aug 14 04:37 PM
Akinsanya KarenSee RemarksAug 12Option Exercise3.1220,06562,60320,065Aug 14 04:53 PM
Akinsanya KarenSee RemarksAug 12Sale67.3220,0651,350,7300Aug 14 04:53 PM
Lorton Kenneth PatrickSee RemarksAug 12Sale67.3038,7892,610,61732,110Aug 14 04:45 PM
Farid RamySee RemarksAug 12Sale67.3280,0005,385,466254,432Aug 14 04:37 PM
Herman JennyVice President, ControllerJun 18Option Exercise1.20345,220Jul 27 04:30 PM
BDTX Black Diamond Therapeutics, Inc. daily Stock Chart
BDTX [NASD]
Black Diamond Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.51 Insider Own2.10% Shs Outstand35.91M Perf Week-10.33%
Market Cap1.03B Forward P/E- EPS next Y-2.50 Insider Trans-25.89% Shs Float33.10M Perf Month7.62%
Income-45.90M PEG- EPS next Q-0.53 Inst Own92.00% Short Float9.71% Perf Quarter9.37%
Sales- P/S- EPS this Y-294.80% Inst Trans-5.00% Short Ratio15.82 Perf Half Y-18.97%
Book/sh9.55 P/B3.09 EPS next Y-18.50% ROA-19.30% Target Price49.25 Perf Year-
Cash/sh5.84 P/C5.05 EPS next 5Y- ROE-30.00% 52W Range17.63 - 46.25 Perf YTD-25.23%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-36.17% Beta-
Dividend %- Quick Ratio33.90 Sales past 5Y- Gross Margin- 52W Low67.44% ATR1.83
Employees32 Current Ratio33.90 Sales Q/Q- Oper. Margin- RSI (14)42.58 Volatility6.52% 5.61%
OptionableNo Debt/Eq0.00 EPS Q/Q-7.80% Profit Margin- Rel Volume0.65 Prev Close29.47
ShortableYes LT Debt/Eq0.00 EarningsAug 11 BMO Payout- Avg Volume203.17K Price29.52
Recom1.60 SMA20-5.90% SMA50-2.60% SMA200-9.93% Volume133,693 Change0.17%
May-04-20Initiated H.C. Wainwright Buy $53
Feb-24-20Initiated JP Morgan Overweight $42
Feb-24-20Initiated Jefferies Buy
Feb-24-20Initiated Cowen Outperform
Feb-24-20Initiated Canaccord Genuity Buy $50
Oct-12-20 07:45AM  
Oct-03-20 08:00AM  
Sep-29-20 07:45AM  
Sep-10-20 07:45AM  
Sep-08-20 04:05PM  
Aug-11-20 07:45AM  
Aug-10-20 08:42AM  
Aug-05-20 07:45AM  
Aug-04-20 07:45AM  
Jul-30-20 09:58AM  
Jul-28-20 07:45AM  
Jun-16-20 07:45AM  
May-27-20 07:45AM  
May-13-20 05:15PM  
May-12-20 07:45AM  
May-06-20 07:45AM  
May-05-20 11:46AM  
Feb-24-20 09:37AM  
Jan-30-20 04:29PM  
Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Versant Venture Capital VI, L.10% OwnerOct 19Sale33.4349416,515995,111Oct 20 08:09 PM
Versant Venture Capital VI, L.10% OwnerOct 19Sale33.433,739124,9985,707,536Oct 20 08:09 PM
Bolzon Bradley J PhDDirectorOct 19Sale33.434,233141,513995,111Oct 20 08:03 PM
Bolzon Bradley J PhDDirectorOct 16Sale33.578,713292,520995,605Oct 20 08:03 PM
Versant Venture Capital VI, L.10% OwnerOct 16Sale33.571,01634,110995,605Oct 20 08:09 PM
Versant Venture Capital VI, L.10% OwnerOct 16Sale33.577,697258,4105,711,275Oct 20 08:09 PM
Versant Venture Capital VI, L.10% OwnerOct 15Sale33.0332710,802996,621Oct 20 08:09 PM
Versant Venture Capital VI, L.10% OwnerOct 15Sale33.032,47381,6945,718,972Oct 20 08:09 PM
Bolzon Bradley J PhDDirectorOct 15Sale33.032,80092,496996,621Oct 20 08:03 PM
Versant Venture Capital VI, L.10% OwnerOct 14Sale33.0964221,244996,948Oct 15 07:22 PM
Versant Venture Capital VI, L.10% OwnerOct 14Sale33.094,859160,7875,721,445Oct 15 07:22 PM
Bolzon Bradley J PhDDirectorOct 14Sale33.095,501182,031996,948Oct 15 07:26 PM
Bolzon Bradley J PhDDirectorOct 13Sale33.3911,739391,984997,590Oct 15 07:26 PM
Versant Venture Capital VI, L.10% OwnerOct 13Sale33.391,36945,713997,590Oct 15 07:22 PM
Versant Venture Capital VI, L.10% OwnerOct 13Sale33.3910,370346,2715,726,304Oct 15 07:22 PM
Hatzis-Schoch BrentSee RemarksOct 12Option Exercise3.204,07813,0507,078Oct 14 04:32 PM
Hatzis-Schoch BrentSee RemarksOct 12Sale32.704,078133,3313,000Oct 14 04:32 PM
Bolzon Bradley J PhDDirectorOct 12Sale33.1140013,243998,959Oct 13 07:48 PM
Versant Venture Capital VI, L.10% OwnerOct 12Sale33.11471,556998,959Oct 13 07:41 PM
Versant Venture Capital VI, L.10% OwnerOct 12Sale33.1135311,6875,736,674Oct 13 07:41 PM
Versant Venture Capital VI, L.10% OwnerOct 09Sale33.6744314,914999,006Oct 13 07:41 PM
Versant Venture Capital VI, L.10% OwnerOct 09Sale33.673,357113,0185,737,027Oct 13 07:41 PM
Bolzon Bradley J PhDDirectorOct 09Sale33.673,800127,933999,006Oct 13 07:48 PM
Leggett ThomasChief Financial OfficerOct 08Option Exercise10.863,00032,5803,000Oct 09 04:12 PM
Bolzon Bradley J PhDDirectorOct 08Sale33.4718,425616,748999,449Oct 13 07:48 PM
Versant Venture Capital VI, L.10% OwnerOct 08Sale33.472,14971,934999,449Oct 13 07:41 PM
Versant Venture Capital VI, L.10% OwnerOct 08Sale33.4716,276544,8145,740,384Oct 13 07:41 PM
Leggett ThomasChief Financial OfficerOct 08Sale33.533,000100,5760Oct 09 04:12 PM
Bolzon Bradley J PhDDirectorOct 07Sale33.5627,836934,0791,041,206Oct 08 07:14 PM
Versant Venture Capital VI, L.10% OwnerOct 07Sale33.563,246108,9241,041,206Oct 08 07:14 PM
Versant Venture Capital VI, L.10% OwnerOct 07Sale33.5624,590825,1545,756,660Oct 08 07:14 PM
Versant Venture Capital VI, L.10% OwnerOct 06Sale33.262,11070,1761,044,452Oct 08 07:14 PM
Versant Venture Capital VI, L.10% OwnerOct 06Sale33.2615,980531,4775,781,250Oct 08 07:14 PM
Bolzon Bradley J PhDDirectorOct 06Sale33.2618,090601,6541,044,452Oct 08 07:14 PM
Roberts Christopher D.Chief Scientific OfficerOct 05Option Exercise10.862,50027,1502,500Oct 07 04:27 PM
Roberts Christopher D.Chief Scientific OfficerOct 05Sale31.282,50078,1880Oct 07 04:27 PM
Epstein David M.See RemarksOct 01Option Exercise6.423,00019,260732,923Oct 02 05:07 PM
Epstein David M.See RemarksOct 01Sale30.3312,000363,962720,923Oct 02 05:07 PM
INGRAM ROBERT ALEXANDERDirectorSep 30Buy30.465,000152,2855,000Oct 01 04:06 PM
Hatzis-Schoch BrentSee RemarksSep 14Option Exercise3.204,07813,0507,078Sep 16 06:11 PM
Leggett ThomasChief Financial OfficerSep 14Option Exercise10.863,00032,5803,000Sep 16 06:09 PM
Hatzis-Schoch BrentSee RemarksSep 14Sale31.044,078126,5833,000Sep 16 06:11 PM
Leggett ThomasChief Financial OfficerSep 14Sale31.003,00093,0000Sep 16 06:09 PM
Roberts Christopher D.Chief Scientific OfficerSep 03Option Exercise10.862,50027,1502,500Sep 04 05:27 PM
Roberts Christopher D.Chief Scientific OfficerSep 03Sale29.592,50073,9870Sep 04 05:27 PM
Bolzon Bradley J PhDDirectorAug 11Sale33.087,575250,5911,125,778Aug 12 07:46 PM
Versant Venture Capital VI, L.10% OwnerAug 11Sale33.0888329,2111,125,778Aug 12 07:57 PM
Versant Venture Capital VI, L.10% OwnerAug 11Sale33.086,692221,3806,797,230Aug 12 07:57 PM
Versant Venture Capital VI, L.10% OwnerAug 10Sale33.0472523,9531,126,661Aug 12 07:57 PM
Versant Venture Capital VI, L.10% OwnerAug 10Sale33.045,492181,4466,803,922Aug 12 07:57 PM
Bolzon Bradley J PhDDirectorAug 10Sale33.046,217205,3981,126,661Aug 12 07:46 PM
FIXX Homology Medicines, Inc. daily Stock Chart
FIXX [NASD]
Homology Medicines, Inc.
Index- P/E- EPS (ttm)-2.79 Insider Own5.41% Shs Outstand45.21M Perf Week-1.40%
Market Cap469.63M Forward P/E- EPS next Y-2.97 Insider Trans0.00% Shs Float42.77M Perf Month-6.04%
Income-124.50M PEG- EPS next Q-0.81 Inst Own98.00% Short Float10.35% Perf Quarter-30.92%
Sales2.20M P/S213.47 EPS this Y-26.80% Inst Trans0.08% Short Ratio9.84 Perf Half Y-17.93%
Book/sh4.31 P/B2.45 EPS next Y6.30% ROA-42.40% Target Price- Perf Year-23.07%
Cash/sh4.65 P/C2.27 EPS next 5Y-9.40% ROE-53.10% 52W Range9.19 - 22.50 Perf YTD-48.94%
Dividend- P/FCF- EPS past 5Y- ROI-42.50% 52W High-53.02% Beta-
Dividend %- Quick Ratio10.70 Sales past 5Y- Gross Margin- 52W Low15.02% ATR0.60
Employees197 Current Ratio10.70 Sales Q/Q50.00% Oper. Margin- RSI (14)45.40 Volatility4.36% 5.41%
OptionableYes Debt/Eq0.00 EPS Q/Q-28.20% Profit Margin- Rel Volume0.57 Prev Close10.78
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume450.18K Price10.57
Recom1.50 SMA20-3.80% SMA50-2.49% SMA200-26.65% Volume259,050 Change-1.95%
Aug-11-20Reiterated H.C. Wainwright Buy $37 → $30
Jun-25-20Resumed BofA/Merrill Buy $30
May-13-20Initiated RBC Capital Mkts Outperform $30
Mar-16-20Upgrade Oppenheimer Perform → Outperform $32
Feb-24-20Initiated Chardan Capital Markets Buy $34
Nov-01-19Initiated Oppenheimer Perform
Sep-10-19Initiated Robert W. Baird Outperform
Apr-12-19Initiated Evercore ISI Outperform
Feb-20-19Initiated H.C. Wainwright Buy $36
Jan-07-19Initiated Canaccord Genuity Buy $37
Sep-07-18Initiated B. Riley FBR Neutral $18.50
Oct-21-20 07:56PM  
12:26PM  
Oct-20-20 07:04PM  
Oct-19-20 03:35PM  
Oct-16-20 04:53PM  
Oct-15-20 01:33PM  
01:30PM  
12:00PM  
11:53AM  
11:30AM  
Oct-14-20 06:23PM  
05:28PM  
Oct-13-20 08:20PM  
04:30PM  
03:12PM  
02:55PM  
01:49PM  
10:55AM  
Oct-12-20 06:10PM  
05:00PM  
Oct-09-20 10:13PM  
04:15PM  
Oct-08-20 09:44PM  
Sep-18-20 09:00AM  
Aug-10-20 05:35PM  
04:05PM  
12:39PM  
12:38PM  
Aug-06-20 12:30PM  
Jul-27-20 11:42PM  
Jul-21-20 08:00AM  
Jul-08-20 08:49AM  
Jun-29-20 10:49AM  
Jun-27-20 02:58PM  
May-26-20 02:11PM  
May-19-20 04:08PM  
May-12-20 08:00AM  
May-10-20 09:45AM  
May-07-20 04:05PM  
Apr-29-20 08:00AM  
Apr-03-20 09:44AM  
Mar-16-20 09:00AM  
Mar-14-20 09:14AM  
Mar-12-20 05:45PM  
04:10PM  
Mar-11-20 09:22AM  
Mar-03-20 12:30PM  
Feb-20-20 09:00AM  
Feb-17-20 10:06AM  
Feb-13-20 09:00AM  
Jan-31-20 11:52AM  
Jan-14-20 08:33AM  
Jan-13-20 02:30PM  
Jan-10-20 02:20PM  
Jan-01-20 08:01AM  
Dec-24-19 10:49AM  
Dec-18-19 10:23AM  
07:23AM  
Dec-17-19 04:01PM  
Dec-16-19 09:00AM  
Dec-13-19 02:44PM  
Dec-03-19 08:30AM  
Nov-26-19 03:00PM  
Nov-12-19 07:35PM  
04:09PM  
Nov-05-19 10:32AM  
Oct-28-19 08:07PM  
Oct-25-19 08:30AM  
Oct-21-19 08:30AM  
Sep-30-19 08:49AM  
Sep-27-19 07:37AM  
Sep-03-19 08:30AM  
Aug-08-19 04:15PM  
Aug-05-19 10:31AM  
Aug-01-19 08:30AM  
Jul-15-19 04:01PM  
Jun-27-19 04:01PM  
Jun-25-19 01:45PM  
Jun-17-19 07:05AM  
Jun-13-19 08:30AM  
Jun-10-19 08:30AM  
May-14-19 09:00AM  
May-13-19 05:55PM  
04:50PM  
04:15PM  
May-09-19 08:45PM  
08:30AM  
May-06-19 10:30AM  
May-02-19 08:00AM  
Apr-30-19 12:00PM  
Apr-15-19 01:05PM  
Apr-09-19 07:08PM  
Apr-08-19 04:10PM  
Apr-04-19 04:05PM  
07:00AM  
Apr-02-19 07:12AM  
Mar-19-19 08:39AM  
Mar-12-19 07:30AM  
07:13AM  
Mar-06-19 08:30AM  
Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing across a range of genetic disorders. The company's various set of AAVHSCs allows company to target, through a single injection, a range of disease-relevant tissues, including the liver, central nervous system, peripheral nervous system, bone marrow, muscle, and eye. Its lead product candidate is HMI-102, which is in Phase 1/2 pheNIX clinical trial, a gene therapy for the treatment of phenylketonuria (PKU) in adults. The company also develops HMI-103 for the treatment of PKU in pediatric patients; and HMI-202 to treat metachromatic leukodystrophy. Homology Medicines, Inc. was founded in 2015 and is based in Bedford, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Kelly Timothy PSee RemarksMar 17Sale13.011,31517,1090Mar 18 05:32 PM
Smith W BradfordCFO, Treasurer & SecretaryFeb 03Option Exercise0.6312,0007,57912,000Feb 05 04:06 PM
Smith W BradfordCFO, Treasurer & SecretaryFeb 03Sale16.1612,000193,8660Feb 05 04:06 PM
TZIANABOS ARTHURPresident & CEOFeb 03Sale16.1612,500202,02177,505Feb 05 04:05 PM
Flynn James EPossible Member of 10% GroupJan 30Sale15.45509,9707,879,0370Jan 31 04:17 PM
Flynn James EPossible Member of 10% GroupJan 29Sale15.458,857136,808509,970Jan 31 04:17 PM
Flynn James EPossible Member of 10% GroupJan 28Sale15.5165,8911,021,936518,827Jan 28 06:38 PM
Flynn James EPossible Member of 10% GroupJan 27Sale15.77193,3593,049,600584,718Jan 28 06:38 PM
Flynn James EPossible Member of 10% GroupJan 24Sale15.69380,2565,965,000778,077Jan 28 06:38 PM
Smith W BradfordCFO, Treasurer & SecretaryJan 02Option Exercise0.636,0003,7906,000Jan 03 05:32 PM
TZIANABOS ARTHURPresident & CEOJan 02Sale20.5012,500256,19190,005Jan 03 05:36 PM
Seymour AlbertChief Scientific OfficerJan 02Sale20.509,133187,216154,017Jan 03 05:33 PM
Smith W BradfordCFO, Treasurer & SecretaryJan 02Sale20.506,000122,9840Jan 03 05:32 PM
Flynn James EPossible Member of 10% GroupDec 24Sale21.95350,0007,682,5351,766,106Dec 27 07:09 PM
Flynn James EPossible Member of 10% GroupDec 23Sale21.83130,9792,859,1931,917,339Dec 23 07:57 PM
Flynn James EPossible Member of 10% GroupDec 20Sale21.5021,129454,2781,973,934Dec 23 07:57 PM
Flynn James EPossible Member of 10% GroupDec 19Sale21.6812,622273,5891,983,064Dec 23 07:57 PM
Smith W BradfordCFO, Treasurer & SecretaryDec 02Option Exercise0.646,0003,8406,000Dec 03 04:07 PM
Seymour AlbertChief Scientific OfficerDec 02Sale16.239,300150,970163,150Dec 03 04:05 PM
Smith W BradfordCFO, Treasurer & SecretaryDec 02Sale16.216,00097,2660Dec 03 04:07 PM
TZIANABOS ARTHURPresident & CEODec 02Sale16.2512,500203,176102,505Dec 03 04:06 PM
Smith W BradfordCFO, Treasurer & SecretaryNov 29Option Exercise0.646,0003,8406,000Dec 03 04:07 PM
Smith W BradfordCFO, Treasurer & SecretaryNov 29Sale16.006,00096,0000Dec 03 04:07 PM
TZIANABOS ARTHURPresident & CEONov 29Sale16.0412,500200,559115,005Dec 03 04:06 PM
Seymour AlbertChief Scientific OfficerNov 29Sale16.069,300149,390172,450Dec 03 04:05 PM
Gregory Richard J.DirectorNov 18Option Exercise0.0310,80632410,806Jan 29 06:43 PM
CABA Cabaletta Bio, Inc. daily Stock Chart
CABA [NASD]
Cabaletta Bio, Inc.
Index- P/E- EPS (ttm)-1.08 Insider Own14.29% Shs Outstand23.02M Perf Week5.29%
Market Cap253.87M Forward P/E- EPS next Y-2.30 Insider Trans0.00% Shs Float22.78M Perf Month6.26%
Income-25.70M PEG- EPS next Q-0.44 Inst Own55.30% Short Float4.79% Perf Quarter-10.40%
Sales- P/S- EPS this Y-71.30% Inst Trans-21.50% Short Ratio12.75 Perf Half Y79.07%
Book/sh5.41 P/B2.13 EPS next Y-41.10% ROA-21.40% Target Price- Perf Year-
Cash/sh5.45 P/C2.12 EPS next 5Y- ROE-27.90% 52W Range5.51 - 19.63 Perf YTD-17.32%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-41.16% Beta-
Dividend %- Quick Ratio37.80 Sales past 5Y- Gross Margin- 52W Low109.62% ATR0.81
Employees31 Current Ratio37.80 Sales Q/Q- Oper. Margin- RSI (14)53.32 Volatility7.10% 7.41%
OptionableNo Debt/Eq0.00 EPS Q/Q-137.80% Profit Margin- Rel Volume0.57 Prev Close11.97
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume85.52K Price11.55
Recom2.00 SMA206.14% SMA504.41% SMA2005.96% Volume49,545 Change-3.51%
Oct-13-20Initiated H.C. Wainwright Buy $20
Nov-19-19Initiated Morgan Stanley Overweight $19
Nov-19-19Initiated Evercore ISI Outperform $25
Nov-19-19Initiated Cowen Outperform
Oct-22-20 07:39AM  
Sep-25-20 08:00AM  
Sep-08-20 08:00AM  
Aug-25-20 08:00AM  
Aug-06-20 07:30AM  
Aug-03-20 08:00AM  
Jul-24-20 07:42AM  
Jul-07-20 08:00AM  
Jun-24-20 04:25PM  
Jun-01-20 12:00PM  
May-28-20 08:00AM  
May-27-20 08:00AM  
May-18-20 04:30PM  
May-12-20 07:00AM  
May-06-20 08:00AM  
Apr-17-20 12:00PM  
Mar-30-20 07:00AM  
Feb-20-20 08:00AM  
Jan-30-20 09:26AM  
Jan-29-20 08:00AM  
Dec-23-19 04:32AM  
Nov-26-19 08:00AM  
Oct-25-19 05:10PM  
07:36AM  
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies. Its product candidate pipeline also include MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. Cabaletta Bio, Inc. has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was founded in 2017 and is headquartered in Philadelphia, Pennsylvania.
FREQ Frequency Therapeutics, Inc. daily Stock Chart
FREQ [NASD]
Frequency Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.58 Insider Own2.30% Shs Outstand31.07M Perf Week1.20%
Market Cap649.80M Forward P/E- EPS next Y-0.40 Insider Trans-20.63% Shs Float26.21M Perf Month-6.23%
Income-18.10M PEG- EPS next Q-0.28 Inst Own53.30% Short Float16.05% Perf Quarter-7.51%
Sales44.70M P/S14.54 EPS this Y-3.30% Inst Trans8.34% Short Ratio27.04 Perf Half Y32.77%
Book/sh5.20 P/B4.05 EPS next Y61.20% ROA-8.90% Target Price35.00 Perf Year53.46%
Cash/sh6.34 P/C3.33 EPS next 5Y- ROE-16.60% 52W Range13.10 - 28.78 Perf YTD20.19%
Dividend- P/FCF27.77 EPS past 5Y- ROI-12.40% 52W High-26.79% Beta-
Dividend %- Quick Ratio4.80 Sales past 5Y- Gross Margin64.20% 52W Low60.84% ATR1.58
Employees47 Current Ratio4.80 Sales Q/Q- Oper. Margin-43.90% RSI (14)50.35 Volatility7.12% 7.29%
OptionableYes Debt/Eq0.00 EPS Q/Q52.30% Profit Margin-40.40% Rel Volume0.64 Prev Close20.66
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume155.59K Price21.07
Recom2.00 SMA202.10% SMA500.34% SMA2003.00% Volume100,261 Change1.98%
Jul-14-20Initiated Oppenheimer Outperform $36
May-18-20Downgrade JP Morgan Overweight → Neutral $27
Oct-28-19Initiated JP Morgan Overweight $25
Oct-28-19Initiated Goldman Buy $30
Oct-28-19Initiated Cowen Outperform
Oct-19-20 10:10AM  
Sep-25-20 09:00AM  
Sep-22-20 07:30AM  
Sep-13-20 03:00PM  
Sep-08-20 08:00AM  
Aug-18-20 02:32PM  
Aug-16-20 08:59AM  
Aug-12-20 07:30AM  
Jul-21-20 09:25AM  
Jul-17-20 04:05PM  
Jun-22-20 02:06PM  
May-27-20 08:00AM  
May-17-20 09:18AM  
May-14-20 07:30AM  
07:15AM  
Mar-26-20 07:00AM  
Feb-21-20 08:30AM  
Feb-07-20 08:00AM  
Jan-07-20 09:00AM  
Nov-18-19 07:30AM  
Nov-12-19 11:40AM  
Oct-11-19 05:01PM  
Oct-10-19 08:30AM  
Oct-02-19 09:09PM  
Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on harnessing the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. Its Progenitor Cell Activation approach, uses combinations of small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in phase 2a clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. Frequency Therapeutics, Inc. has a licencse and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322. Frequency Therapeutics, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Loose Christopher R.Chief Scientific OfficerOct 13Sale22.008,000176,00087,782Oct 14 04:29 PM
Loose Christopher R.Chief Scientific OfficerOct 08Sale21.128,000168,96095,782Oct 08 05:54 PM
Loose Christopher R.Chief Scientific OfficerOct 07Sale20.008,000160,010103,782Oct 08 05:54 PM
Loose Christopher R.Chief Scientific OfficerOct 06Sale19.468,000155,680111,782Oct 08 05:54 PM
Loose Christopher R.Chief Scientific OfficerOct 05Sale18.358,000146,800119,782Oct 05 05:14 PM
Loose Christopher R.Chief Scientific OfficerOct 02Sale18.928,000151,360127,782Oct 05 05:14 PM
Loose Christopher R.Chief Scientific OfficerOct 01Sale18.848,000150,720135,782Oct 05 05:14 PM
Lucchino David L.President and CEOOct 01Sale19.1315,716300,658355,228Oct 05 04:26 PM
Loose Christopher R.Chief Scientific OfficerSep 23Sale21.134,50095,097143,782Sep 25 08:55 AM
Loose Christopher R.Chief Scientific OfficerSep 09Sale18.974,50085,369148,282Sep 10 04:56 PM
Lucchino David L.President and CEOSep 01Sale18.5515,714291,474370,944Sep 03 04:16 PM
Loose Christopher R.Chief Scientific OfficerAug 19Sale22.974,500103,350152,782Aug 20 04:29 PM
Loose Christopher R.Chief Scientific OfficerAug 05Sale21.214,50095,464157,282Aug 06 05:15 PM
Lucchino David L.President and CEOAug 03Sale21.6315,714339,829386,658Aug 05 05:05 PM
Loose Christopher R.Chief Scientific OfficerJul 22Sale21.514,50096,791161,782Jul 23 05:10 PM
MARCUS JOEL SDirectorJul 20Buy18.0055,555999,9901,011,730Jul 22 06:12 PM
Loose Christopher R.Chief Scientific OfficerJul 08Sale22.324,500100,439166,282Jul 10 04:30 PM
Lucchino David L.President and CEOJul 01Sale22.4515,714352,833402,372Jul 02 04:59 PM
Loose Christopher R.Chief Scientific OfficerJun 24Sale22.804,500102,587170,782Jun 25 06:18 PM
Loose Christopher R.Chief Scientific OfficerJun 10Sale19.964,50089,829175,282Jun 12 05:13 PM
Mitrano Richard J.VP Finance & OperationsJun 03Option Exercise0.473,4811,62215,015Jun 04 06:33 PM
Lucchino David L.President and CEOJun 02Sale18.573,83971,276418,086Jun 04 06:32 PM
Lucchino David L.President and CEOJun 01Sale17.9111,875212,654421,925Jun 02 04:40 PM
MARCUS JOEL SDirectorMay 21Sale18.815,00094,053319,700May 22 05:54 PM
Loose Christopher R.Chief Scientific OfficerMay 20Sale19.024,50085,611187,282May 22 05:56 PM
MARCUS JOEL SDirectorMay 20Sale18.765,00093,796324,700May 20 05:35 PM
MARCUS JOEL SDirectorMay 19Sale18.407,809143,671329,700May 20 05:35 PM
MARCUS JOEL SDirectorMay 18Sale19.1515,000287,189337,509May 20 05:35 PM
Lucchino David L.President and CEOMay 08Sale18.1810,478190,494433,800May 12 04:32 PM
Loose Christopher R.Chief Scientific OfficerMay 06Sale16.284,50073,268191,782May 07 05:05 PM
Lucchino David L.President and CEOMay 05Sale16.195,23984,835444,278May 07 04:41 PM
Lucchino David L.President and CEOMay 01Sale15.285,23679,997449,517May 04 04:15 PM
Lucchino David L.President and CEOApr 24Sale16.3572911,919454,753Apr 28 04:02 PM
Lucchino David L.President and CEOApr 23Sale16.081,41022,674455,482Apr 24 05:06 PM
Loose Christopher R.Chief Scientific OfficerApr 22Sale14.844,50066,794196,282Apr 24 04:52 PM
Lucchino David L.President and CEOApr 17Sale16.003,10049,600456,892Apr 21 04:29 PM
Lucchino David L.President and CEOApr 15Sale15.135,23679,234459,992Apr 17 03:53 PM
Loose Christopher R.Chief Scientific OfficerApr 08Sale14.994,50067,469200,782Apr 10 03:17 PM
COHEN MARC ADirectorJan 30Option Exercise2.6088,116228,688605,820Feb 03 04:05 PM
Lucchino David L.President and CEODec 30Option Exercise0.6157,37735,000465,228Jan 02 04:06 PM
MIRM Mirum Pharmaceuticals, Inc. daily Stock Chart
MIRM [NASD]
Mirum Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.23 Insider Own10.32% Shs Outstand25.00M Perf Week-10.21%
Market Cap451.81M Forward P/E- EPS next Y-4.69 Insider Trans0.00% Shs Float22.78M Perf Month-9.66%
Income-77.60M PEG- EPS next Q-0.98 Inst Own81.90% Short Float2.75% Perf Quarter-16.11%
Sales- P/S- EPS this Y-202.90% Inst Trans0.14% Short Ratio8.83 Perf Half Y22.15%
Book/sh5.45 P/B3.26 EPS next Y-25.40% ROA-49.00% Target Price- Perf Year139.03%
Cash/sh5.87 P/C3.03 EPS next 5Y- ROE-54.60% 52W Range6.51 - 28.31 Perf YTD-27.57%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-37.27% Beta-
Dividend %- Quick Ratio9.20 Sales past 5Y- Gross Margin- 52W Low172.70% ATR1.16
Employees54 Current Ratio9.20 Sales Q/Q- Oper. Margin- RSI (14)35.90 Volatility6.53% 5.77%
OptionableNo Debt/Eq0.00 EPS Q/Q-57.90% Profit Margin- Rel Volume0.41 Prev Close18.23
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume70.95K Price17.76
Recom1.40 SMA20-8.40% SMA50-16.52% SMA200-2.64% Volume29,502 Change-2.58%
Aug-07-20Upgrade Raymond James Outperform → Strong Buy $28 → $48
Aug-03-20Initiated H.C. Wainwright Buy $52
Jul-31-20Initiated Piper Sandler Overweight $77
Jun-25-20Initiated Robert W. Baird Outperform $30
Aug-12-19Initiated ROTH Capital Buy $33
Aug-12-19Initiated Raymond James Outperform $28
Aug-12-19Initiated Guggenheim Buy $18
Aug-12-19Initiated Evercore ISI Outperform
Aug-12-19Initiated Citigroup Buy $21
Oct-15-20 08:55AM  
08:45AM  
Oct-14-20 10:29AM  
Oct-13-20 04:05PM  
Sep-11-20 04:30PM  
07:00AM  
Sep-01-20 09:00AM  
Aug-29-20 08:45AM  
Aug-11-20 05:30PM  
09:42AM  
09:37AM  
Aug-07-20 04:05PM  
Aug-06-20 04:05PM  
Jul-10-20 05:00PM  
Jun-22-20 02:06PM  
Jun-11-20 04:10PM  
Jun-02-20 08:30AM  
May-29-20 10:05AM  
May-11-20 05:01PM  
May-07-20 04:05PM  
Apr-28-20 04:19PM  
Mar-12-20 04:02PM  
Feb-18-20 04:01PM  
Jan-16-20 09:00AM  
Jan-14-20 09:00AM  
Jan-08-20 08:15PM  
Dec-24-19 10:40AM  
Dec-17-19 07:56AM  
Dec-16-19 08:00AM  
Dec-13-19 04:28PM  
Nov-25-19 08:30AM  
08:30AM  
Nov-08-19 08:05AM  
Nov-06-19 04:05PM  
Oct-28-19 04:05PM  
08:30AM  
Oct-21-19 10:15AM  
Oct-01-19 04:30PM  
Sep-26-19 08:35AM  
08:30AM  
Aug-28-19 04:01PM  
Aug-12-19 09:57AM  
Jul-17-19 06:33PM  
Jul-15-19 10:10AM  
Jul-12-19 12:10PM  
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its lead product candidate is maralixibat, an investigational oral drug that is in Phase 3 clinical trial for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. The company is also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was founded in 2018 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tucker Edwin JonathanChief Medical OfficerMar 20Buy11.902,50029,7406,000Mar 23 04:47 PM
Tucker Edwin JonathanChief Medical OfficerMar 19Buy9.912,00019,8183,500Mar 23 04:47 PM
ACRS Aclaris Therapeutics, Inc. daily Stock Chart
ACRS [NASD]
Aclaris Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.67 Insider Own3.90% Shs Outstand42.13M Perf Week6.25%
Market Cap166.86M Forward P/E- EPS next Y-1.14 Insider Trans0.00% Shs Float38.92M Perf Month70.00%
Income-69.50M PEG- EPS next Q-0.30 Inst Own67.70% Short Float1.78% Perf Quarter89.73%
Sales5.50M P/S30.34 EPS this Y-10.10% Inst Trans-5.14% Short Ratio1.32 Perf Half Y308.65%
Book/sh1.17 P/B3.63 EPS next Y11.60% ROA-91.80% Target Price- Perf Year163.98%
Cash/sh1.73 P/C2.45 EPS next 5Y- ROE-153.90% 52W Range0.70 - 5.04 Perf YTD124.87%
Dividend- P/FCF- EPS past 5Y-57.10% ROI-158.70% 52W High-15.67% Beta1.42
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin18.40% 52W Low507.14% ATR0.39
Employees77 Current Ratio4.00 Sales Q/Q122.20% Oper. Margin- RSI (14)64.35 Volatility9.70% 11.48%
OptionableYes Debt/Eq0.23 EPS Q/Q74.10% Profit Margin- Rel Volume0.79 Prev Close4.52
ShortableYes LT Debt/Eq0.21 Earnings- Payout- Avg Volume524.90K Price4.25
Recom1.20 SMA2022.57% SMA5051.54% SMA200135.55% Volume420,094 Change-5.97%
Oct-22-19Upgrade SVB Leerink Mkt Perform → Outperform
Sep-06-19Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jun-27-19Downgrade SVB Leerink Outperform → Mkt Perform
May-06-19Initiated SVB Leerink Outperform $13
Mar-28-18Resumed Leerink Partners Outperform $52
Feb-09-18Initiated Guggenheim Buy $53
Jun-16-17Initiated Cantor Fitzgerald Overweight $50
Nov-29-16Initiated Leerink Partners Outperform $54
Sep-30-16Initiated JMP Securities Mkt Outperform
Jun-10-16Initiated Guggenheim Buy $35
Nov-02-15Initiated Jefferies Buy $20
Nov-02-15Initiated Citigroup Buy
Oct-21-20 10:46AM  
Oct-20-20 07:00AM  
Oct-14-20 10:36PM  
Oct-01-20 12:00PM  
Sep-30-20 06:40AM  
Sep-01-20 04:01PM  
Aug-13-20 12:00PM  
Aug-07-20 08:45AM  
07:00AM  
Aug-06-20 12:30PM  
Jul-08-20 08:43AM  
Jul-07-20 04:01PM  
Jun-26-20 02:30PM  
Jun-18-20 10:12AM  
Jun-17-20 10:37AM  
07:01AM  
Jun-03-20 07:00AM  
May-26-20 04:01PM  
May-12-20 10:47AM  
May-08-20 12:00PM  
May-07-20 04:01PM  
May-06-20 12:30PM  
Apr-09-20 06:13AM  
Apr-06-20 12:00PM  
Apr-01-20 11:07AM  
Mar-31-20 04:01PM  
Mar-17-20 02:46AM  
Feb-25-20 04:01PM  
Feb-24-20 07:31AM  
Feb-19-20 05:00PM  
Feb-10-20 07:00AM  
Jan-13-20 05:03PM  
Jan-10-20 07:13AM  
05:40AM  
Jan-09-20 04:27PM  
Jan-08-20 08:00AM  
Dec-24-19 12:00PM  
Dec-12-19 10:33AM  
Nov-27-19 03:23PM  
Nov-21-19 11:39AM  
Nov-18-19 05:34PM  
Nov-17-19 07:14AM  
Nov-12-19 04:01PM  
Nov-07-19 04:01PM  
Oct-31-19 04:01PM  
Oct-29-19 10:33AM  
Oct-25-19 07:12AM  
Oct-24-19 04:01PM  
Oct-17-19 09:46AM  
Oct-14-19 10:28AM  
Oct-11-19 11:46AM  
Oct-10-19 04:02PM  
Oct-09-19 07:58AM  
Oct-08-19 05:01PM  
01:42PM  
Oct-07-19 07:25AM  
Oct-06-19 10:00AM  
Oct-03-19 07:28AM  
Sep-30-19 12:15PM  
10:44AM  
Sep-28-19 06:30PM  
10:00AM  
Sep-27-19 08:15PM  
03:00PM  
12:21PM  
11:00AM  
10:36AM  
Sep-26-19 04:45PM  
04:45PM  
11:17AM  
08:19AM  
Sep-25-19 08:48PM  
03:38PM  
03:15PM  
11:00AM  
10:35AM  
09:00AM  
Sep-24-19 09:10PM  
03:15PM  
03:09PM  
01:05PM  
Sep-23-19 10:34AM  
09:35AM  
Sep-20-19 03:00PM  
11:31AM  
11:00AM  
10:44AM  
Sep-19-19 07:40PM  
01:30PM  
11:30AM  
Sep-18-19 07:51PM  
05:45PM  
12:23PM  
10:42AM  
Sep-17-19 08:49PM  
02:45PM  
12:29PM  
11:15AM  
07:23AM  
07:00AM  
Aclaris Therapeutics, Inc., a biopharmaceutical company, focuses on developing drug candidates for immuno-inflammatory diseases in the United States. It operates in two segments, Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor. It is also developing A-101, a high-concentration formulation of hydrogen peroxide that is in Phase III clinical trial for common warts; and ATI-501 and ATI-502 Janus kinase (JAK) inhibitors, which are in Phase II clinical trials for alopecia areata (AA) and other dermatological indications. In addition, the company's products under development include ATI-450 an investigational oral, novel, small molecule selective MK2 inhibitor compound for the treatment of rheumatoid arthritis; ATI-1777 soft inhibitor for atopic dermatitis; and ATI-2138, an investigational oral ITK/TXK/JAK3, or ITJ, inhibitor compound, for the treatment of psoriasis inflammatory bowel disease. Further, it provides contract research services. Aclaris Therapeutics, Inc. has a license and collaboration agreement with Rigel Pharmaceuticals, Inc. for the development and commercialization of JAK inhibitors. The company was founded in 2012 and is headquartered in Wayne, Pennsylvania.
SWAV ShockWave Medical, Inc. daily Stock Chart
SWAV [NASD]
ShockWave Medical, Inc.
Index- P/E- EPS (ttm)-2.11 Insider Own1.80% Shs Outstand32.16M Perf Week-2.93%
Market Cap2.32B Forward P/E- EPS next Y-1.55 Insider Trans-81.66% Shs Float31.82M Perf Month1.85%
Income-64.60M PEG- EPS next Q-0.55 Inst Own95.00% Short Float8.15% Perf Quarter55.44%
Sales51.10M P/S45.49 EPS this Y-40.00% Inst Trans-4.99% Short Ratio5.62 Perf Half Y91.82%
Book/sh7.63 P/B9.38 EPS next Y29.90% ROA-29.40% Target Price70.80 Perf Year118.81%
Cash/sh7.12 P/C10.05 EPS next 5Y50.50% ROE-35.70% 52W Range22.01 - 79.74 Perf YTD62.91%
Dividend- P/FCF- EPS past 5Y- ROI-25.10% 52W High-10.27% Beta-
Dividend %- Quick Ratio13.60 Sales past 5Y- Gross Margin62.50% 52W Low225.08% ATR3.49
Employees284 Current Ratio14.90 Sales Q/Q3.00% Oper. Margin- RSI (14)46.78 Volatility5.99% 4.24%
OptionableYes Debt/Eq0.07 EPS Q/Q-48.90% Profit Margin- Rel Volume0.70 Prev Close74.05
ShortableYes LT Debt/Eq0.07 EarningsAug 11 AMC Payout- Avg Volume461.64K Price71.55
Recom2.00 SMA20-4.70% SMA506.07% SMA20048.70% Volume326,387 Change-3.38%
Jun-11-20Upgrade Oppenheimer Underperform → Perform
Apr-01-20Downgrade Oppenheimer Perform → Underperform
Feb-21-20Upgrade BofA/Merrill Neutral → Buy $47 → $50
Dec-12-19Upgrade Wells Fargo Market Perform → Outperform $49
Oct-22-19Initiated Oppenheimer Perform
Oct-21-19Initiated Piper Jaffray Overweight $39
Jun-13-19Reiterated BofA/Merrill Neutral $44 → $64
Apr-01-19Initiated Wells Fargo Market Perform
Apr-01-19Initiated Morgan Stanley Equal-Weight $32
Apr-01-19Initiated BofA/Merrill Neutral $37
Oct-20-20 08:00AM  
06:04AM  
Oct-15-20 12:35PM  
Oct-01-20 08:00AM  
Aug-26-20 08:00AM  
Aug-12-20 05:30AM  
Aug-11-20 07:00PM  
05:55PM  
04:05PM  
Aug-04-20 12:30PM  
Jul-30-20 08:00AM  
Jul-21-20 04:05PM  
04:05PM  
Jul-20-20 08:00AM  
Jul-09-20 05:23PM  
08:09AM  
Jul-06-20 07:50AM  
Jul-04-20 07:32AM  
Jun-16-20 08:20PM  
07:39AM  
Jun-09-20 07:46AM  
Jun-08-20 04:30PM  
May-13-20 06:31AM  
May-12-20 05:25PM  
04:03PM  
May-05-20 12:30PM  
Apr-30-20 08:00AM  
Apr-21-20 04:05PM  
Apr-13-20 08:00AM  
Apr-06-20 08:00AM  
Feb-17-20 10:56AM  
Feb-13-20 04:03PM  
Jan-21-20 04:05PM  
Jan-17-20 02:11PM  
Jan-03-20 10:15AM  
Dec-19-19 04:12PM  
Nov-14-19 10:00PM  
Nov-12-19 04:13PM  
Nov-08-19 08:30AM  
Nov-07-19 04:03PM  
08:30AM  
Nov-04-19 09:45AM  
08:55AM  
08:30AM  
Nov-01-19 10:26AM  
10:23AM  
Oct-26-19 01:20PM  
Oct-17-19 04:03PM  
Sep-25-19 11:00AM  
Sep-18-19 10:15AM  
Sep-12-19 12:56PM  
Sep-10-19 11:15PM  
Sep-09-19 08:14AM  
Sep-04-19 02:59PM  
Sep-03-19 03:50PM  
08:30AM  
Sep-01-19 09:00AM  
Aug-26-19 02:27PM  
07:18AM  
Aug-23-19 07:37AM  
07:11AM  
Aug-21-19 08:30AM  
Aug-06-19 11:21AM  
Aug-05-19 11:17PM  
04:03PM  
Aug-03-19 04:05PM  
Jul-23-19 07:18PM  
04:03PM  
04:03PM  
Jul-22-19 01:22PM  
Jul-19-19 10:13AM  
Jul-17-19 08:01AM  
Jul-06-19 11:11AM  
Jul-05-19 12:26PM  
Jul-01-19 02:08PM  
07:39AM  
Jun-12-19 04:14PM  
Jun-11-19 07:14AM  
Jun-10-19 08:00AM  
Jun-07-19 05:00PM  
10:43AM  
08:34AM  
Jun-04-19 07:21AM  
May-24-19 02:38PM  
09:36AM  
May-21-19 11:24AM  
May-15-19 08:00AM  
May-10-19 04:23PM  
04:14PM  
02:55PM  
May-09-19 04:07PM  
07:33AM  
May-08-19 10:39PM  
05:31PM  
04:03PM  
09:30AM  
07:57AM  
May-03-19 10:45AM  
May-02-19 03:35PM  
May-01-19 08:30AM  
ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company operates in the United States, Germany, rest of Europe, and internationally. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Papiernik AntoineDirectorOct 19Sale79.229,500752,5901,466,006Oct 20 04:41 PM
Papiernik AntoineDirectorOct 16Sale79.017,119562,4721,475,506Oct 20 04:41 PM
PUCKETT DANChief Financial OfficerOct 15Option Exercise2.4812,00029,80449,308Oct 16 09:27 PM
Zacharias IsaacChief Commercial OfficerOct 15Option Exercise4.034,00016,10462,550Oct 16 08:53 PM
PUCKETT DANChief Financial OfficerOct 15Sale74.3012,000891,56937,308Oct 16 09:27 PM
Zacharias IsaacChief Commercial OfficerOct 15Sale73.244,000292,95058,550Oct 16 08:53 PM
Papiernik AntoineDirectorOct 12Sale79.0045535,9451,482,625Oct 13 08:42 PM
Papiernik AntoineDirectorOct 09Sale79.001,12688,9541,483,080Oct 13 08:42 PM
Papiernik AntoineDirectorOct 06Sale77.004,413339,8011,484,206Oct 06 09:34 PM
Papiernik AntoineDirectorOct 05Sale77.1524,5871,896,8871,488,619Oct 06 09:34 PM
Papiernik AntoineDirectorOct 01Sale77.031,00077,0301,513,206Oct 01 06:50 PM
Papiernik AntoineDirectorSep 30Sale75.2216,7441,259,4841,514,206Oct 01 06:50 PM
Papiernik AntoineDirectorSep 29Sale75.0213,256994,4651,530,950Sep 29 09:06 PM
Papiernik AntoineDirectorSep 28Sale73.1317,3471,268,5861,544,206Sep 29 09:06 PM
Papiernik AntoineDirectorSep 18Sale73.1912,653926,0731,561,553Sep 21 09:52 PM
Papiernik AntoineDirectorSep 15Sale71.1141,4722,948,9591,574,206Sep 15 08:06 PM
Papiernik AntoineDirectorSep 14Sale67.9878,5285,338,4271,615,678Sep 15 08:06 PM
Zacharias IsaacChief Commercial OfficerSep 10Option Exercise6.713,18321,35862,550Sep 11 07:42 PM
Zacharias IsaacChief Commercial OfficerSep 10Sale66.614,000266,42158,550Sep 11 07:42 PM
Zacharias IsaacChief Commercial OfficerSep 03Option Exercise4.0324,80099,84559,367Sep 04 09:04 PM
Godshall Douglas EvanPresident & CEOAug 27Option Exercise3.428492,90099,208Aug 28 07:40 PM
Papiernik AntoineDirectorAug 27Sale60.52132,9978,049,6021,694,206Aug 27 09:18 PM
Godshall Douglas EvanPresident & CEOAug 27Sale60.0084950,94098,359Aug 28 07:40 PM
Papiernik AntoineDirectorAug 26Sale60.0123,5451,412,9351,854,646Aug 26 09:43 PM
Godshall Douglas EvanPresident & CEOAug 25Option Exercise3.4248,761166,568147,120Aug 25 07:19 PM
Papiernik AntoineDirectorAug 25Sale60.0560,6573,642,4531,878,191Aug 26 09:43 PM
Godshall Douglas EvanPresident & CEOAug 25Sale60.0648,7612,928,58698,359Aug 25 07:19 PM
PUCKETT DANChief Financial OfficerAug 24Option Exercise2.205271,15737,835Aug 25 07:21 PM
Godshall Douglas EvanPresident & CEOAug 24Option Exercise3.429,35931,970107,718Aug 25 07:19 PM
Papiernik AntoineDirectorAug 24Sale60.0027,4431,646,5801,827,203Aug 27 09:18 PM
Godshall Douglas EvanPresident & CEOAug 24Sale60.009,359561,54098,359Aug 25 07:19 PM
PUCKETT DANChief Financial OfficerAug 24Sale60.0052731,62037,308Aug 25 07:21 PM
Godshall Douglas EvanPresident & CEOAug 21Option Exercise3.4216,75057,218115,109Aug 21 09:51 PM
PUCKETT DANChief Financial OfficerAug 21Option Exercise2.203,8668,49041,174Aug 21 09:50 PM
PUCKETT DANChief Financial OfficerAug 21Sale60.023,866232,03737,308Aug 21 09:50 PM
Papiernik AntoineDirectorAug 21Sale60.0221,5361,292,5911,938,848Aug 21 09:52 PM
Sofinnova Capital VII FCPR10% OwnerAug 21Sale60.0221,5361,292,5911,938,848Aug 21 09:52 PM
Godshall Douglas EvanPresident & CEOAug 21Sale60.0216,7501,005,33598,359Aug 21 09:51 PM
PUCKETT DANChief Financial OfficerAug 20Option Exercise2.375,60713,29342,915Aug 21 09:50 PM
Godshall Douglas EvanPresident & CEOAug 20Option Exercise3.4227,27693,175125,635Aug 21 09:51 PM
Godshall Douglas EvanPresident & CEOAug 20Sale60.0127,2761,636,83398,359Aug 21 09:51 PM
Papiernik AntoineDirectorAug 20Sale60.0133,8222,029,6581,960,384Aug 21 09:52 PM
PUCKETT DANChief Financial OfficerAug 20Sale60.045,607336,64437,308Aug 21 09:50 PM
Sofinnova Capital VII FCPR10% OwnerAug 20Sale60.0133,8222,029,6581,960,384Aug 21 09:52 PM
Sofinnova Capital VII FCPR10% OwnerAug 19Sale56.5989,8785,086,4161,994,206Aug 20 04:22 PM
Papiernik AntoineDirectorAug 19Sale56.5989,8785,086,4161,994,206Aug 20 04:26 PM
Cahill ColinDirectorAug 18Option Exercise17.005,79398,4818,494Aug 20 04:29 PM
Cahill ColinDirectorAug 18Sale55.051,832100,8526,662Aug 20 04:29 PM
Papiernik AntoineDirectorAug 18Sale55.08133,9227,376,4242,084,084Aug 20 04:26 PM
Sofinnova Capital VII FCPR10% OwnerAug 18Sale55.08133,9227,376,4242,084,084Aug 20 04:22 PM
Sofinnova Capital VII FCPR10% OwnerAug 17Sale55.0461,8233,402,7382,218,006Aug 20 04:22 PM
Papiernik AntoineDirectorAug 17Sale55.0461,8233,402,7382,218,006Aug 20 04:26 PM
Sofinnova Capital VII FCPR10% OwnerAug 13Sale55.0113,077719,3662,555,265Aug 14 07:48 PM
Papiernik AntoineDirectorAug 13Sale55.0113,077719,3662,555,265Aug 14 07:50 PM
Papiernik AntoineDirectorAug 12Sale55.021,30071,5262,568,342Aug 14 07:50 PM
Sofinnova Capital VII FCPR10% OwnerAug 12Sale55.021,30071,5262,568,342Aug 14 07:48 PM
Zacharias IsaacChief Commercial OfficerAug 10Option Exercise5.104,00020,41238,567Aug 11 04:02 PM
Zacharias IsaacChief Commercial OfficerAug 10Sale51.864,000207,43634,567Aug 11 04:02 PM
Sofinnova Capital VII FCPR10% OwnerAug 06Sale50.9371,7223,652,7092,534,096Aug 10 05:29 PM
Papiernik AntoineDirectorAug 06Sale50.9371,7223,652,7092,534,096Aug 10 05:27 PM
Papiernik AntoineDirectorAug 05Sale50.71109,4065,547,9972,605,818Aug 05 09:51 PM
Sofinnova Capital VII FCPR10% OwnerAug 05Sale50.71109,4065,547,9972,605,818Aug 05 09:50 PM
Godshall Douglas EvanPresident & CEOAug 04Option Exercise3.4219,35766,124117,716Aug 05 09:49 PM
PUCKETT DANChief Financial OfficerAug 04Option Exercise2.201,4303,14038,738Aug 05 09:50 PM
Sofinnova Capital VII FCPR10% OwnerAug 04Sale50.0133,3231,666,4832,715,224Aug 05 09:50 PM
Godshall Douglas EvanPresident & CEOAug 04Sale50.0119,357968,05398,359Aug 05 09:49 PM
Papiernik AntoineDirectorAug 04Sale50.0133,3231,666,4832,715,224Aug 05 09:51 PM
PUCKETT DANChief Financial OfficerAug 04Sale50.011,43071,51437,308Aug 05 09:50 PM
PUCKETT DANChief Financial OfficerAug 03Option Exercise2.208,57018,82045,878Aug 05 09:50 PM
Godshall Douglas EvanPresident & CEOAug 03Option Exercise3.4210,64336,356109,002Aug 05 09:49 PM
PUCKETT DANChief Financial OfficerAug 03Sale50.028,570428,67137,308Aug 05 09:50 PM
Sofinnova Capital VII FCPR10% OwnerAug 03Sale50.0185,5494,278,3052,748,547Aug 05 09:50 PM
Godshall Douglas EvanPresident & CEOAug 03Sale50.0210,643532,38998,359Aug 05 09:49 PM
Papiernik AntoineDirectorAug 03Sale50.0185,5494,278,3052,748,547Aug 05 09:51 PM
Zacharias IsaacChief Commercial OfficerJul 10Option Exercise4.034,00016,10438,567Jul 13 09:25 PM
Zacharias IsaacChief Commercial OfficerJul 10Sale43.194,000172,77234,567Jul 13 09:25 PM
Zacharias IsaacChief Commercial OfficerJun 10Option Exercise4.034,00016,10438,567Jun 10 07:12 PM
Zacharias IsaacChief Commercial OfficerJun 10Sale46.894,000187,56034,567Jun 10 07:12 PM
Sofinnova Capital VII FCPR10% OwnerJun 10Sale46.7929,7291,391,0202,834,096Jun 11 09:38 PM
Papiernik AntoineDirectorJun 10Sale46.7929,7291,391,0202,834,096Jun 11 09:37 PM
Sofinnova Capital VII FCPR10% OwnerJun 09Sale46.92141,3426,631,2392,863,825Jun 11 09:38 PM
Papiernik AntoineDirectorJun 09Sale46.92141,3426,631,2392,863,825Jun 11 09:37 PM
Sofinnova Capital VII FCPR10% OwnerJun 08Sale45.1159,8792,701,1423,005,167Jun 08 07:33 PM
Papiernik AntoineDirectorJun 08Sale45.1159,8792,701,1423,005,167Jun 08 07:35 PM
Sofinnova Capital VII FCPR10% OwnerJun 05Sale45.0455,7542,511,1603,065,046Jun 08 07:33 PM
Papiernik AntoineDirectorJun 05Sale45.0455,7542,511,1603,065,046Jun 08 07:35 PM
Sofinnova Capital VII FCPR10% OwnerJun 04Sale45.034,000180,1203,120,800Jun 08 07:33 PM
Papiernik AntoineDirectorJun 04Sale45.034,000180,1203,120,800Jun 08 07:35 PM
Sofinnova Capital VII FCPR10% OwnerJun 03Sale45.027,996359,9803,124,800Jun 03 09:31 PM
Papiernik AntoineDirectorJun 03Sale45.027,996359,9803,124,800Jun 03 09:32 PM
Papiernik AntoineDirectorJun 01Sale45.001,30058,5003,132,796Jun 03 09:32 PM
Sofinnova Capital VII FCPR10% OwnerJun 01Sale45.001,30058,5003,132,796Jun 03 09:31 PM
Godshall Douglas EvanPresident & CEOMay 15Option Exercise3.4230,000102,480128,359May 19 04:14 PM
Godshall Douglas EvanPresident & CEOMay 15Sale41.9530,0001,258,59398,359May 19 04:14 PM
Zacharias IsaacChief Commercial OfficerMay 11Option Exercise4.034,00016,10438,567May 12 04:27 PM
Zacharias IsaacChief Commercial OfficerMay 11Sale41.134,000164,51434,567May 12 04:27 PM
Zacharias IsaacChief Commercial OfficerApr 13Option Exercise4.034,00016,10439,000Apr 15 07:45 PM
Zacharias IsaacChief Commercial OfficerApr 13Sale35.344,000141,34935,000Apr 15 07:45 PM
Zacharias IsaacChief Commercial OfficerMar 10Option Exercise4.034,00016,10439,000Mar 12 05:20 PM
Zacharias IsaacChief Commercial OfficerMar 10Sale36.614,000146,44335,000Mar 12 05:20 PM
XERS Xeris Pharmaceuticals, Inc. daily Stock Chart
XERS [NASD]
Xeris Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.97 Insider Own2.50% Shs Outstand37.97M Perf Week-1.86%
Market Cap254.49M Forward P/E- EPS next Y-1.65 Insider Trans5.50% Shs Float37.53M Perf Month-19.66%
Income-119.20M PEG- EPS next Q-0.52 Inst Own72.40% Short Float46.70% Perf Quarter85.56%
Sales6.00M P/S42.41 EPS this Y-66.60% Inst Trans0.43% Short Ratio5.02 Perf Half Y187.98%
Book/sh0.64 P/B8.23 EPS next Y33.70% ROA-91.80% Target Price- Perf Year-33.46%
Cash/sh2.98 P/C1.77 EPS next 5Y- ROE-435.30% 52W Range1.42 - 9.69 Perf YTD-25.25%
Dividend- P/FCF- EPS past 5Y- ROI-167.70% 52W High-45.61% Beta-
Dividend %- Quick Ratio6.70 Sales past 5Y- Gross Margin21.80% 52W Low271.13% ATR0.49
Employees188 Current Ratio6.90 Sales Q/Q566.70% Oper. Margin- RSI (14)48.44 Volatility8.51% 8.90%
OptionableYes Debt/Eq0.00 EPS Q/Q50.40% Profit Margin- Rel Volume0.43 Prev Close5.25
ShortableYes LT Debt/Eq4.49 EarningsAug 10 BMO Payout- Avg Volume3.49M Price5.27
Recom1.60 SMA20-6.85% SMA504.15% SMA20031.50% Volume1,516,000 Change0.38%
Feb-18-20Initiated Piper Sandler Overweight $12
Jul-16-18Initiated RBC Capital Mkts Outperform $24
Jul-16-18Initiated Leerink Partners Outperform $24
Jul-16-18Initiated Jefferies Buy $23
Oct-21-20 08:04AM  
05:30AM  
Oct-20-20 04:05PM  
Oct-19-20 01:41PM  
Oct-12-20 08:21PM  
Oct-02-20 04:05PM  
Sep-22-20 03:52PM  
Sep-08-20 08:00AM  
Aug-28-20 04:05PM  
Aug-26-20 10:35AM  
Aug-21-20 07:43AM  
Aug-20-20 04:15PM  
Aug-18-20 08:57AM  
Aug-11-20 08:49AM  
Aug-10-20 04:00PM  
08:25AM  
07:56AM  
07:00AM  
Aug-03-20 04:05PM  
Jul-31-20 04:05PM  
Jul-30-20 08:00AM  
Jul-28-20 12:33PM  
Jul-15-20 04:05PM  
Jul-12-20 05:56AM  
Jul-06-20 08:02AM  
Jul-01-20 07:00AM  
Jun-30-20 08:03PM  
08:46AM  
Jun-26-20 04:05PM  
Jun-25-20 09:32PM  
Jun-24-20 04:01PM  
Jun-18-20 08:00AM  
Jun-15-20 09:19AM  
06:00AM  
May-29-20 04:05PM  
May-26-20 10:11AM  
May-22-20 08:00AM  
May-14-20 02:14PM  
03:00AM  
May-09-20 05:02PM  
May-07-20 10:35AM  
09:36AM  
07:00AM  
Apr-30-20 08:00AM  
Apr-29-20 07:00AM  
Apr-28-20 06:43AM  
Apr-20-20 08:00AM  
Mar-27-20 05:30PM  
Mar-26-20 04:15PM  
Mar-19-20 08:00AM  
Mar-16-20 08:10AM  
Mar-11-20 07:30AM  
06:00AM  
Mar-04-20 12:30PM  
Feb-28-20 04:05PM  
Feb-27-20 04:05PM  
Feb-20-20 04:05PM  
Feb-18-20 09:00AM  
Feb-12-20 09:18AM  
Feb-11-20 07:07PM  
Feb-10-20 04:06PM  
Jan-31-20 04:05PM  
Jan-07-20 07:57AM  
Jan-06-20 05:01PM  
04:05PM  
Dec-29-19 09:40PM  
Dec-27-19 04:05PM  
Dec-22-19 05:09PM  
Dec-11-19 07:21AM  
Dec-10-19 05:33PM  
Dec-02-19 06:37AM  
Nov-29-19 01:05PM  
Nov-21-19 06:00AM  
Nov-07-19 03:09PM  
11:45AM  
08:00AM  
Nov-01-19 04:05PM  
Oct-30-19 10:33AM  
Oct-25-19 02:22PM  
Oct-01-19 08:00AM  
Sep-27-19 04:05PM  
Sep-19-19 08:00AM  
Sep-10-19 11:58AM  
11:43AM  
11:31AM  
11:30AM  
07:36AM  
Sep-04-19 11:34AM  
Aug-30-19 04:05PM  
Aug-29-19 05:00PM  
Aug-06-19 07:45PM  
04:05PM  
Aug-05-19 10:31AM  
Aug-02-19 04:05PM  
Jul-18-19 01:09PM  
Jun-28-19 04:05PM  
Jun-27-19 08:00AM  
Jun-17-19 08:00AM  
May-25-19 09:03AM  
May-09-19 04:05PM  
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technology platforms allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, small molecules, and proteins using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company's lead product candidate is Gvoke HypoPen for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise ready-to-use glucagon that has completed Phase II clinical trials for the treatment of post-bariatric hypoglycemia, exercise-induced hypoglycemia in diabetes, bi-hormonal artificial pancreas closed-loop systems, congenital hyperinsulinism, and hypoglycemia-associated autonomic failure; and hypoglycemia associated with intermittent and chronic conditions. In addition, it develops ready-to-use diazepam formulation, which is in Phase Ib clinical trial for the treatment of Dravet syndrome and acute repetitive seizures in patients with epilepsy; and Pramlintide-Insulin co-formulation that is Phase II clinical trials for treating type 1 and 2 diabetes. Xeris Pharmaceuticals, Inc. serves patients, caregivers, and health practitioners. The company was founded in 2005 and is headquartered in Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Shannon John Patrick JrSee RemarksMay 13Buy3.5522,00077,994117,493May 14 04:30 PM
Shannon John Patrick JrSee RemarksMay 08Buy3.207,88625,21995,493May 11 06:17 PM
Edick Paul RSee RemarksMay 08Buy3.0033,00099,000401,134May 11 05:06 PM
Hecht BethSee RemarksMar 13Buy1.974,0007,88057,083Mar 16 04:07 PM
Hecht BethSee RemarksFeb 14Buy4.154,00016,6008,083Feb 18 05:02 PM
Shannon John Patrick JrSee RemarksFeb 14Buy4.1512,04849,99922,607Feb 18 05:02 PM
Edick Paul RSee RemarksFeb 14Buy4.1520,00083,000183,134Feb 18 05:02 PM
JOHNSON KENNETH ERLANDSee RemarksFeb 14Buy4.152,41010,0026,115Feb 18 04:59 PM
Deutsch Barry M.See RemarksFeb 14Buy4.159,63940,00239,359Feb 18 04:55 PM
PRESTRELSKI STEVENChief Scientific OfficerJan 13Sale5.5010,00054,992421,824Jan 14 04:40 PM
Edick Paul RSee RemarksNov 25Buy8.5517,935153,283172,935Nov 27 04:43 PM
ARVN Arvinas, Inc. daily Stock Chart
ARVN [NASD]
Arvinas, Inc.
Index- P/E- EPS (ttm)-2.34 Insider Own0.60% Shs Outstand38.74M Perf Week-19.91%
Market Cap1.59B Forward P/E- EPS next Y-2.91 Insider Trans-1.31% Shs Float24.53M Perf Month-22.88%
Income-85.70M PEG- EPS next Q-0.68 Inst Own93.20% Short Float23.12% Perf Quarter-41.24%
Sales46.90M P/S33.88 EPS this Y72.20% Inst Trans-0.03% Short Ratio14.83 Perf Half Y-61.37%
Book/sh5.11 P/B3.95 EPS next Y-11.50% ROA-32.50% Target Price- Perf Year23.18%
Cash/sh3.08 P/C6.55 EPS next 5Y- ROE-44.50% 52W Range15.39 - 61.57 Perf YTD-50.86%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-67.21% Beta-
Dividend %- Quick Ratio7.40 Sales past 5Y- Gross Margin- 52W Low31.19% ATR1.53
Employees133 Current Ratio7.40 Sales Q/Q42.50% Oper. Margin- RSI (14)31.45 Volatility8.00% 6.03%
OptionableYes Debt/Eq0.00 EPS Q/Q-19.30% Profit Margin- Rel Volume1.67 Prev Close20.97
ShortableYes LT Debt/Eq0.01 EarningsAug 04 BMO Payout- Avg Volume382.43K Price20.19
Recom1.80 SMA20-16.70% SMA50-20.18% SMA200-47.18% Volume636,054 Change-3.72%
Jun-01-20Upgrade Citigroup Neutral → Buy $45
May-12-20Initiated Oppenheimer Perform
Dec-19-19Initiated H.C. Wainwright Buy $50
Nov-25-19Initiated Guggenheim Buy $50
Oct-24-19Upgrade Goldman Neutral → Buy $23 → $38
Sep-25-19Initiated Wedbush Outperform $38
Sep-12-19Initiated BMO Capital Markets Outperform
Aug-06-19Initiated Cantor Fitzgerald Overweight $42
Jun-05-19Downgrade Citigroup Buy → Neutral $21 → $22
Apr-12-19Initiated Evercore ISI Outperform
Oct-22-18Initiated Piper Jaffray Overweight $23